The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1658
September 5, 2022
View Complete Issue         Table of Contents 2019 
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
September 5, 2022 (Issue: 1658)
The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to or cannot tolerate one or more tumor...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
Article code: 1658d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.